SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The 401jK (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and the popular US based 401(k) retirement plan and other pension plans around the world  Through the meme fueled humor, irony, satire &amp; inspiration from cypherpunk ideology, real life data, and current events... the 401jK community aims to comment on the fact that global markets are heavily manipulated for selfish purposes by the same people who control these pension funds... while also aiming to twist the heads of the 401k and global pension systems.  It is a retirement plan that seeks to make social, political, economic commentary fueled by the memes and dreams of the hive mind of the community that makes up 401jK  The rules have changed, and the game was always rigged.  It's time to wake up, adapt, rebel, and heal.  Welcome to 401jK

401jK

The 401jK community is leveraging viral, anti-establishment memes to build a grassroots movement that mocks traditional retirement systems and advocates for financial independence. While some critics label the token a volatile pump-and-dump scheme, supporters maintain strong conviction, pointing to sustained community activity, staking mechanics, and IRL marketing efforts as evidence of a long-term project aimed at disrupting rigged financial structures.

"What's Updog?" is a Community Led token.

UpDog

The UpDog community is driving strong social engagement through playful memes and high-energy interaction while actively coordinating community-led events like poker nights. Investors are frequently discussing whale accumulation and emphasizing the ticker's longevity in the crypto space as they look for potential breakout momentum.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as investors focus on the upcoming AACR conference data presentation, while the community intensely debates the potential for a short squeeze amid high short interest and heavy options volume. While bulls emphasize the promise of clinical candidates like GPS and SLS009 for AML treatment, bears continue to raise concerns regarding trial design, clinical data consistency, and the company's financial runway.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi is seeing significant volatility as investors digest the CEO's departure and speculate on the company's future leadership, with the community actively debating whether this transition marks a positive turning point or a deeper systemic issue for the data center project. Trading activity remains intense as participants monitor options flow and look for clarity on potential anchor tenant contracts and upcoming strategic updates.

AEVEX Corp. operates as a holding company. It operates through Tactical Systems and Global Solutions segments. The Tactical Systems segment focuses on design, development, and production of autonomous systems including unmanned aerial systems and unmanned surface vessels. The Global Solutions segment offers services and mission support to defense and intelligence customers. The company was founded in 2017 and is headquartered in Solana Beach, CA.

AEVEX Corp. - Ordinary Shares - Class A

AEVEX Corp. is seeing intense market interest following a strong NYSE debut as investors capitalize on its positioning within the drone and autonomous defense systems sector. The community is actively debating the stock's momentum potential, fueled by media commentary and comparisons to other high-growth IPOs, while closely monitoring after-hours trading activity.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is trending as the community highlights its 2011 origin story as the original crypto parody, positioning the asset as a foundational piece of digital culture rather than a typical meme. Supporters point to substantial whale accumulation and locked supply as evidence of long-term conviction, while the coin remains a polarizing figure that continues to generate significant engagement through its controversial history.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group is experiencing intense volatility driven by a massive, ongoing short squeeze that has captivated the community and triggered fierce debates between retail traders over the sustainability of the stock's parabolic ascent. While bulls point to high institutional ownership and the potential for further upside, many participants are concerned by the stock's lack of fundamental backing and are actively monitoring for a sharp, sentiment-driven reversal.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound is currently a focal point of community debate, driven by a combination of its low circulating supply and investor speculation surrounding upcoming DeFi governance updates and potential institutional partnerships. While some traders are expressing optimism over a technical breakout and the potential for a supply-driven rally, others remain skeptical, pointing to governance challenges and comparative weakness against sector peers like AAVE.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull Corp is seeing a surge in investor optimism driven by the recent SEC approval to eliminate the pattern day trader rule, which the community expects to significantly boost platform trading volumes. Bulls are actively discussing potential short squeezes and fundamental undervaluation compared to industry peers, fueling high sentiment for a potential run toward double digits.

Portillo's, Inc. serves street food through high-energy, multichannel restaurants designed to ignite the senses and create a memorable dining experience. The company was founded on June 8, 2021 and is headquartered in Oak Brook, IL.

Portillos Inc - Ordinary Shares - Class A

Portillo's is currently a focal point for investors debating a potential turnaround, driven by a mixture of heavy short interest, technical oversold conditions, and community enthusiasm for new restaurant openings in markets like Georgia. While some participants are wary of leadership transitions and margin pressures, many in the community are actively accumulating shares and highlighting the company's brand loyalty and unit-level performance as catalysts for a future rebound.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Last month, the company said that SLS009 blocks key survival pathways that normally shield acute myeloid leukemia cells from natural programmed cell death, making them more vulnerable.</li><li>Pharmacodynamic changes were observed in AML cells as early as eight hours after treatment and became more pronounced over time, the company noted.</li><li>Meanwhile, Sellas’s late-stage trial of its lead candidate GPS in Acute Myeloid Leukemia is advancing toward final analysis.</li></ul>Shares of Sellas Life Sciences Group Inc. (SLS) closed up 6% and edged up 2% after-hours on Friday, garnering heavy retail interest as investors anticipated upcoming data updates on its pipeline at the American Association for Cancer Research.According to Stocktwits platform data, retail chatter increased 36% over the past day, rising from ‘low’ to ‘normal’ levels.Sellas is slated to present preclinical data on its experimental cancer therapy SLS009 in a poster session at the conference which started on April 17 and is slated to go till April 22 at the San Diego Convention Center. Sellas will make its presentation on April 21.<h2 class="st-heading-2">Pipeline Optimism</h2>Last month, the company said that SLS009 blocks key survival pathways that normally shield acute myeloid leukemia (AML) cells from natural programmed cell death, making them more vulnerable. Pharmacodynamic changes were observed in AML cells as early as eight hours after treatment and became more pronounced over time, the company noted.“The ability to lower apoptotic threshold in AML cells by suppressing key survival pathways and enhancing potency with repeated exposure further supports the development of SLS009, including in combination regimens,” said Dragan Cicic, Chief Development Officer of SELLAS.Sellas’s lead candidate, GPS, meanwhile, is being evaluated for its potential as a monotherapy and in combination with other therapies to address a broad spectrum of blood malignancies and solid tumor indications.The company’s late-stage trial of GPS in Acute Myeloid Leukemia is advancing toward final analysis. The final analysis is slated for when the company records the 80th patient death in the trial. In December, the company announced that 72 events had been completed and it will announce when the 80th event occurs. With event-driven trials like Sellas’s, the delay highlights longer survival, indicating potential for the therapy.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around SLS stock rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours.A Stocktwits user said that the stock has two near-term catalysts in terms of the upcoming conference and update on the GPS program in AML.<stembedurl>https://www.stocktwits.com/55X_ROI_Q1_2026/message/650652881</stembedurl>Yet another sounded optimistic for the company’s pipeline, highlighting the many designations granted to Sellas’s experimental therapies.<stembedurl>https://www.stocktwits.com/gata2016/message/650649884</stembedurl><a href="https://stocktwits.com/symbol/SLS">SLS stock</a> has nearly quadrupled over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-on-track-for-best-day-in-nearly-16-months-whats-driving-the-rally/cZJyGq6RIUn">CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Last week, Baird maintained AYI’s ‘neutral’ rating but cut price target to $320 from $375. (Representative image: Getty Images)

SLS Stock Sparks Retail Buzz Ahead of AACR Presentation On Experimental Cancer Therapy

Sellas is slated to announce preclinical data on its experimental cancer therapy SLS009 in a poster session at the conference which started on April 17 and is slated to go till April 22 at the San Diego Convention Center.

Equity

Sellas is slated to announce preclinical data on its experimental cancer therapy SLS009 in a poster session at the conference which started on April 17 and is slated to go till April 22 at the San Diego Convention Center.


<ul class="summary-bullets"><li>Sellas will present new data on its CDK9 inhibitor SLS009 at the American Association for Cancer Research (AACR) meeting on April 21.</li><li>Preclinical findings showed SLS009 triggered leukemia cell death by increasing caspase-3 activity and reducing survival proteins such as MCL-1 and survivin.</li><li>Investor focus remains centered on the Phase 3 Regal study evaluating GPS as a maintenance therapy for AML patients in remission after relapse.</li></ul>Shares of Sellas Life Sciences Group, Inc. (SLS) rose 1% in premarket trading on Thursday as investors positioned ahead of an upcoming cancer conference presentation and a closely watched survival milestone in the company’s Phase 3 acute myeloid leukemia (AML) trial.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> jumped 8% on Wednesday amid a volatile trading week.<h2 class="st-heading-2">AACR Preview: SLS009 Triggers Leukemia Cell Death Signals</h2>Sellas is preparing to present new preclinical data on its CDK9 inhibitor candidate SLS009 at the American Association for Cancer Research (AACR) annual meeting on April 21 in San Diego.Preclinical findings showed that SLS009 triggered leukemia cell death by increasing&nbsp;the&nbsp;activity of caspase-3, a key apoptosis protein, while lowering survival signals such as MCL-1 and survivin that help cancer cells persist. The drug also became more potent with repeated exposure, with early effects appearing within hours and strengthening over 24 hours.Notably, SLS009 remained active even in AML models carrying ASXL1 and TP53 mutations, which are associated with treatment resistance and poorer outcomes.<h2 class="st-heading-2">Investor Focus Remains On AML Survival Readout Timeline</h2>However, investor attention remains firmly focused on the company’s Phase 3 Regal trial evaluating GPS as a maintenance therapy for AML patients whose disease returned but later entered remission following additional treatment.GPS targets the Wilms Tumor-1 antigen, a protein commonly expressed across leukemia cells regardless of mutation status.The event-driven study will begin final analysis once 80 overall-survival events are recorded. Sellas previously said the contract research organization monitoring the trial had logged 72 events as of Dec. 26, bringing the study closer to the threshold required to initiate topline analysis.CEO Angelos Stergiou recently addressed speculation surrounding the timing of the readout on&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.linkedin.com/feed/update/urn:li:activity:7444461539476197376/?originTrackingId=ExoqDp%2B3Mqnf9Ee3j3DVgA%3D%3D">LinkedIn</a>, noting that slower accumulation of survival events in oncology trials can sometimes indicate patients are living longer than baseline expectations.Once the 80th event occurs, the company plans to proceed with database lock, statistical analysis, unblinding and disclosure of topline results.<h2 class="st-heading-2">How Does Retail Feel About SLS?</h2>On Stocktwits, retail sentiment for SLS has slipped to ‘bearish’ from ‘extremely bullish’ levels a month ago amid a 23% dip in message volumes over the past week.<figure class="image"><img src="https://news.stocktwits-cdn.com/sls_ss_png_d73af252d9.webp" alt="sls ss.png" width="965" height="143"><figcaption>SLS sentiment and message volume as of April 9 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/Princeb/message/649792805">said</a> SLS is “truly shaping up to be a once in a lifetime moonshot win.&nbsp; Don't miss your chance.”<stembedurl>https://stocktwits.com/Princeb/message/649792805</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Torben96/message/649792114">said</a>, “GPS is a safe harbour now, the IDMC meeting will reveal this. We should be worth 2B Dollar already.”<stembedurl>https://stocktwits.com/Torben96/message/649792114</stembedurl>SLS stock has surged 367% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bbby-ceo-pulls-opendoor-into-everything-home-turnaround-bet/cZJgy2ORIrB">Bed Bath &amp; Beyond CEO Pulls Opendoor Into ‘Everything-Home’ Platform Pivot</a>

SLS stock has surged 367% over the past year. (Photo credit: Getty Images)

SLS Stock Rises Premarket Ahead Of Cancer Summit This Month – Investors Eye Phase 3 AML Trial Milestone

SLS Stock - CEO Angelos Stergiou recently said that the slower accumulation of survival events can sometimes reflect longer patient survival.

CEO Angelos Stergiou recently said that the slower accumulation of survival events can sometimes reflect longer patient survival.

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Up 9.5%  - What's Next?

SELLAS Life Sciences Group (NASDAQ:SLS) Trading 9.5% Higher - Here's What Happened...

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 7.7%  - Here's Why

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 7.7% - What's Next...

All You Need to Know About SELLAS Life Sciences Group, Inc. (SLS) Rating Upgrade to Buy

SELLAS Life Sciences Group, Inc. (SLS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Wall Street Analysts Believe SELLAS Life Sciences Group, Inc. (SLS) Could Rally 63.58%: Here's is How to Trade

The consensus price target hints at a 63.6% upside potential for SELLAS Life Sciences Group, Inc. (SLS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

<ul class="summary-bullets"><li>Investors weighed conflicting signals from Middle East diplomacy and braced for fresh labor market data.</li><li>AI trade tensions and regulatory risks kept Nvidia and chip-linked names under pressure.</li><li>U.S. President Trump will be holding a cabinet meeting at 10:00 am ET today.&nbsp;</li></ul>U.S. stock futures fell early Thursday as investors continued to parse the geopolitical developments in the Middle East. Amid conflicting reports, Iran is said to be reviewing a U.S. peace proposal delivered through Pakistan. Traders are also bracing for fresh macro signals with jobless claims data due later today. U.S. President Trump will be holding a cabinet meeting at 10:00 am ET today.&nbsp;As of 4:00 a.m. ET on Thursday, Dow, S&amp;P 500, and Nasdaq futures fell 0.4%, and Russell 2000 futures were down 0.6%.Retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, and the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq-100 Index, has been languishing at ‘extremely bearish’ amid high trading volume.&nbsp;Trending Stocks To WatchNvidia (NVDA):&nbsp;The chipmaker remains in focus, with retail sentiment weakening to ‘bearish’ on Stocktwits. Calls are growing louder in Washington, with U.S. Senators Warren and Banks pushing to freeze export licenses over national security concerns.Meta Inc (META):&nbsp;It has lost another lawsuit alleging they made misleading claims about platform safety, adding to its growing list of legal headwinds.Destiny Tech100 (DXYZ):&nbsp;Garnering heavy retail interest as speculation around a potential SpaceX IPO grows this week.Micron (MU), Sandisk (SNDK):&nbsp;Memory stocks took a hit after reports that Google’s new AI model architecture could bring a significant impact on memory requirements.Super Micro (SMCI): The stock remained under pressure as shareholders filed a securities fraud lawsuit following recent allegations of chip smuggling.ImmunityBio (IBRX): The retail favorite biotech stock is back on traders’ radar after the company highlighted progress in its bladder cancer program and expanded trials targeting severe pneumonia and ARDS.&nbsp;Sellas Life Sciences (SLS): This pharma stock is gaining ground amid&nbsp;retail-trader speculation that Pfizer (PFE) may target the firm for an acquisition.urban-Gro (UGRO): The stock fell over 10% in early pre-market trading after surging over 400% in the previous session. Retail is bullish on the company’s new exposure to India’s fast-growing cricket economy following its merger with Flash Sports &amp; Media.Other tickers trending on&nbsp;Stocktwits&nbsp;at the time of writing included Adma Biologics (ADMA), Upstart Holdings (UPST), Moonlake Immunotherapeutics (MLTX), NextDecade Corporation (NEXT), and Alphabet Inc (GOOGL).&nbsp;Other Catalysts To WatchOn the economic front, traders will be watching for the release of continuing jobless claims data at 8:30 am ET. Also keep an eye on commentary from a whole host of Fed Governors’ speeches through the day, including Fed Vice Chair for Supervision Michael Barr.On earnings radar, watch out for quarterly reports from Pulmatrix (PULM), BioRestorative Therapies Inc (BRTX), and POET Technologies Inc (POET), among others, today.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Fall Ahead Of Jobless Claims Data: Why NVDA, META, DXYZ, IBRX, SLS Are Keeping Traders Engaged Today

Data from Stocktwits shows that traders remain ‘extremely bearish’ on SPY and QQQ. 

<ul class="summary-bullets"><li>Investors compared Merck’s willingness to pay a 42% premium for mid-stage leukemia drug TERN-701 with Sellas’ AML pipeline opportunity.</li><li>Several retail investors pointed to Pfizer as a potential buyer, citing its ongoing expansion in hematologic cancers and need for post-COVID growth drivers.</li><li>Attention is focused on the Phase 3 Regal trial of GPS in AML relapse patients, which had recorded 72 of 80 required death events for final analysis as of late December.</li></ul>Shares of Sellas Life Sciences (SLS)&nbsp;jumped over 6% on Wednesday as Merck’s $6.7 billion acquisition of Terns Pharmaceuticals triggered renewed buzz on potential takeover targets across blood-cancer drug pipelines.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> has risen 41% this quarter and has surged over 300% over the past year.<h2 class="st-heading-2">Merck’s Terns Deal Spurs Leukemia Interest</h2>Merck said it would acquire Terns for $53 per share in cash, representing a 42% premium to the 90-day average before the deal’s announcement.The acquisition adds TERN-701, an oral leukemia drug currently in early-to-mid-stage clinical testing, to Merck’s blood-cancer pipeline. The treatment is being studied for patients with chronic myeloid leukemia whose disease did not respond well to earlier therapies or who could not tolerate them.Now, retail investors are drawing comparisons between Merck’s willingness to pay billions for a mid-stage leukemia asset and the perceived commercial opportunity around Sellas’ pipeline.<h2 class="st-heading-2">Retail Traders Bet On Pfizer As Potential Buyer</h2>On Stocktwits, retail sentiment for SLS has remained in the ‘bearish’ zone over the past week amid an over 350% surge in message volume this quarter. The stock’s watcher base has jumped 20% over the past year.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/sls_ss_png_7ab67c1205.webp" alt="sls ss.png" width="968" height="144"><figcaption>SLS sentiment and message volume as of March 26 | Source: Stocktwits</figcaption></figure>Sentiment over the past day has increasingly centered on Pfizer as a potential acquirer following the Merck-Terns deal. One trader&nbsp;<a href="https://stocktwits.com/MarcoFla99/message/648580457">said</a>, “My $$ is on PFE to acquire SLS.”The investor pointed to Pfizer’s ongoing clinical work on Mylotarg in CD33-positive acute myeloid leukemia (AML), noting that the company is conducting a prospective surveillance study to evaluate the drug’s safety and effectiveness in newly diagnosed patients as part of its push into hematologic cancers.Another trader argued Pfizer may be seeking a major oncology win following the pandemic-era revenue decline,&nbsp;<a href="https://stocktwits.com/OnTheBalance/message/648587881">saying</a>, “They need a clear win to bury the COVID era and leave it behind… What is better than a cancer moonshot?”Another investor&nbsp;<a href="https://stocktwits.com/OnTheBalance/message/648587881">highlighted</a> motivations behind possible acquisitions, saying “PFE stock and shareholders [are] looking desperately for a powerful boost.”<h2 class="st-heading-2">Retail Traders Run Buyout Valuation Scenarios</h2>One retail investor&nbsp;<a href="https://stocktwits.com/Duncan74/message/648577739">estimated</a> that applying a typical 5x-8x peak-sales multiple to projected revenue of about $5.5 billion for Sellas’ lead AML candidate, Galinpepimut-S (GPS), and $1.2 billion for its CDK9 inhibitor, SLS-009, could imply a valuation range of roughly $33.5 billion to $53.6 billion.Another trader compared the Merck-Terns transaction directly with Sellas’ opportunity: “If TERN was acquired by MRK for 8.8b. and our product has market size smaller than TERN. our upside should be 4x-6x?”A separate user discussed potential acquisition structure scenarios,&nbsp;<a href="https://stocktwits.com/JdlawVT40/message/648584776">saying</a>, “Wouldn’t a PFE stock purchase be sweet. All long term holding period and a 6.30 dividend. Four to one share SLS.”Another trader&nbsp;<a href="https://stocktwits.com/Johnmtnb2018/message/648533707">suggested</a> the setup for a deal may already be in place: “The table is now fully set for interested pharma’s to finish a deal!” One investor also&nbsp;<a href="https://stocktwits.com/Laacy/message/648584092">outlined</a> a portfolio strategy for a possible acquisition, saying, “If PFE offers id sell my options. Keep 33% as pfizer shares if share based and sell the rest.”<h2 class="st-heading-2">GPS Catalyst Aligns With Pfizer Moves</h2>Investor attention remains focused on Sellas’ Phase 3 Regal trial evaluating GPS in AML patients whose cancer returned and then went back into remission after additional treatment. The study is designed to reach its final analysis after 80 patient death events, with 72 recorded as of Dec. 26 while the trial remained fully blinded, placing the program closer to a potential results-driven catalyst.Merck’s move to buy TERN-701 underscores continued demand for blood-cancer assets, while Pfizer has been stepping up investment in oncology as it looks to rebuild growth after the sharp decline in COVID vaccine revenues and increasing competition across several aging products.&nbsp;The company has expanded its cancer pipeline through initiatives including its $1.25 billion upfront licensing deal with 3SBio, ongoing development of Mylotarg in AML and progress with Tukysa in breast cancer.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sls-vs-tern-which-stock-has-more-upside-ahead-of-keytruda-patent-cliff/cZ3YKepRI16">SLS Vs. TERN: Which Pharma Stock Has More Upside As Merck Eyes $6B Cancer Bet Ahead Of Keytruda Patent Cliff</a>

SLS stock has risen 41% this quarter and has surged over 300% over the past year. (Photo credit: Getty Images)

SLS Stock Jumps After Merck's Tern Deal Sparks Buyout Buzz In Blood-Cancer Space: Retail Bets On This Big Pharma Suitor

Merck’s acquisition of Terns underscores strong big-pharma demand for blood-cancer assets, as Pfizer also expands its oncology pipeline.

Medicine pill is seen with Merck logo displayed on a screen in the background in this illustration photo taken in Poland on November 5, 2021. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

SLS Vs. TERN: Which Pharma Stock Has More Upside As Merck Eyes $6B Cancer Bet Ahead Of Keytruda Patent Cliff

SLS vs TERN Stock - Analyst estimates suggest SLS may offer 73% upside, versus 16% for TERN, despite takeover momentum supporting TERN’s shares.

Analyst estimates suggest SLS may offer 73% upside, versus 16% for TERN, despite takeover momentum supporting TERN’s shares.

SELLAS Life Sciences Group (NASDAQ:SLS) Trading Down 8.5%  - Here's Why

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 8.5% - Time to Sell...

Bullish continuation

Sideways chop

Fade lower

Full reversal

The market rebounded fast this week — what’s your call for next week?

Stocktwits

Stocktwits Polls

Retail investors are aggressively targeting short-sellers and call-writers as open interest increases, pushing for a massive covering event.

Investors are buzzing with anticipation for the upcoming AACR presentation, hoping that new clinical data will serve as a major price catalyst.

Persistent speculation regarding a potential multi-billion dollar acquisition by big pharma has investors positioning for a transformative exit.

The stock finished the week strong during Options Expiration, with bulls celebrating an impressive close despite skepticism from bearish sentiment meters.

Long-term bulls are rallying around the clinical promise of pipeline assets like GPS and SLS009, viewing the stock as a life-saving mission.

Current Price	$5.22
Prev Close	$4.93
Open	$5.10
Dividend Yield	0.00%
50-Day Moving Average	$4.69
Beta	0.81
Avg. Volume	8.3M
PE Ratio	-21.23

52-Week High	$6.14
52-Week Low	$1.27
Market Capitalization	$885.34M
EPS (Annual)	-$0.2463
Price to Book	11.28
Revenue Per Employee	$0.00

SLS
SELLAS Life Sciences Group Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SLS News

SLSSELLAS Life Sciences Group Inc